Table 7 Comparison of screening performance measuresa of frailty assessment instruments
From: Frailty in end-stage renal disease: comparing patient, caregiver, and clinician perspectives
FI >0.21 | FI >0.45 | |
|---|---|---|
CFS ≥4 | ||
Sensitivity | 71 (58–81) | 90 (68–99) |
Specificity | 72 (53–87) | 51 (39–62) |
PPV | 86 (77–92) | 31 (26–37) |
NPV | 51 (41–62) | 95 (84–99) |
CFS ≥5 | ||
Sensitivity | 47 (35–60) | 70 (46–88) |
Specificity | 100 (88–100) | 77 (66–86) |
PPV | 100 (81–100) | 43 (31–55) |
NPV | 45 (39–50) | 91 (84–95) |
FACT-CFS ≥4 | ||
Sensitivity | 94 (86–98) | 95 (75–100) |
Specificity | 48 (29–68) | 21 (13–32) |
PPV | 81 (75–86) | 23 (21–26) |
NPV | 78 (56–91) | 94 (70–99) |
FACT-CFS ≥5 | ||
Sensitivity | 62 (50–74) | 85 (62–97) |
Specificity | 100 (87–100) | 66 (54–76) |
PPV | 100 (84–100) | 38 (30–47) |
NPV | 53 (45–60) | 95 (86–98) |
DMMS-Frail | ||
Sensitivity | 97 (90–100) | 100 (83–100) |
Specificity | 70 (50–86) | 28 (18–39) |
PPV | 88 (81–93) | 26 (23–28) |
NPV | 91 (72–98) | 100 (75–100) |